Efficacy and safety of a novel submucosal injection solution for endoscopic resection in porcine models

J Dig Dis. 2021 Jan;22(1):49-56. doi: 10.1111/1751-2980.12963. Epub 2020 Dec 21.

Abstract

Objective: A submucosal injection is usually required to improve the efficacy and safety of endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR). This study aimed to evaluate the performance of 3.3% sodium carboxymethyl starch (Na-CMS) solution, a novel submucosal injection solution, for ESD and EMR.

Methods: Na-CMS, normal saline (NS) and two commercially available agents (sigMAVisc and Eleview) were injected into the esophageal submucosa of randomly grouped pigs. The level of submucosal elevation was examined. Subsequently, ESD or EMR procedures using 3.3% Na-CMS or NS as submucosal injections were performed in the gastrointestinal tract of the pigs.

Results: Submucosal elevation was significantly higher and more sustained in the 3.3% Na-CMS group than in the controls (P < 0.05). The volume required for ESD or EMR was significantly lower in the 3.3% Na-CMS group than in the NS group (ESD: 12.21 ± 4.09 mL vs 28.25 ± 8.02 mL, P < 0.001; EMR: 3.99 ± 1.98 mL vs 7.15 ± 3.67 mL, P = 0.001). The ESD resection time was significantly shorter in the 3.3% Na-CMS group than in the NS group (16.58 ± 7.30 min vs 25.29 ± 11.89 min, P = 0.004). Hemorrhage after ESD in the 3.3% Na-CMS group was less severe than that in the NS group (P = 0.006).

Conclusion: 3.3% Na-CMS is an effective, safe and low-cost submucosal injection solution and holds promise as preferable agent for submucosal injection in ESD and EMR procedures.

Keywords: endoscopic mucosal resection; endoscopic submucosal dissection; sodium carboxymethyl starch; submucosal injection.

MeSH terms

  • Animals
  • Endoscopic Mucosal Resection*
  • Esophagus
  • Injections
  • Poloxamer
  • Swine
  • Treatment Outcome

Substances

  • SIC-8000
  • Poloxamer